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A B S T R A C T
In this study, we examined the possible roles of ceramide/sphingosine-1-phosphate and ceramide/
glucosyleceramide signaling in docetaxel-induced apoptosis by examining expression levels of the
glucosyleceramide synthase and sphingosine kinase-1 and ceramide synthase gene family. As confirmed
by isobologram analysis, docetaxel in combination with agents that increase intracellular ceramide
levels increased the cytotoxic and apoptotic effects of docetaxel synergistically. More importantly, RT-
PCR results revealed that expression levels of glucosyleceramide synthase and sphingosine kinase-1
were downregulated and ceramide synthase genes were upregulated in response to docetaxel. This
study identifies mechanisms underlying the involvement of ceramide metabolizing genes in docetaxel-
induced apoptosis in prostate cancer cells.
 2012 Elsevier Masson SAS. All rights reserved.
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Prostate cancer is the second leading cause of cancer-related
deaths in men [1,2]. Chemotherapy provides the treatment of
choice for the effective management of androgen-independent
prostate cancer (AIPC). Docetaxel is a very effective anticancer
agent used for the treatment of various types of cancers including
prostate cancer [2–4]. Docetaxel inhibits microtubule depolymeri-
zation, resulting in cell cycle arrest and apoptosis [3,5,6].
Ceramides are lipid second messengers that mediate various
cellular functions including cell growth, proliferation, drug
resistance, and apoptosis. Many external factors, such as radiation
and chemotherapeutics regulate endogenous ceramide levels [7].
Ceramides can be generated via de novo synthesis by the longevity
assurance gene family (LASS) and via hydrolization of sphingo-
myelin by sphingomiyelinase. Cell-permeable ceramide analogs/
mimetics have antiproliferative and apoptotic effects in various
types of tumor cells [8,9]. However, aberrations in the generation
of ceramides have been linked to resistance to cell death [10].
While increases in endogenous ceramide levels in response to
chemotherapy were observed, there were also aberrations in
bioactive sphingolipids in chemoresistant cells.
Glucosylceramide synthase (GCS) converts ceramides into
antiapoptotic glucosylceramide. Since, GCS is over-expressed in
almost all types of multidrug resistant cancer cells, it has been* Corresponding author. Tel.: +90 232 7507515; fax: +90 232 7507509.
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doi:10.1016/j.biopha.2011.10.003suggested as a potential marker of drug resistance [11,12]. In
addition to GCS’s roles in regulating proliferation and oncogenic
transformation, it was shown that certain anticancer agents induce
apoptosis through downregulating expression levels of GCS [13].
Sphingosine-1-phosphate (S1P), the product of SK-1, is shown to be
an antiapoptotic lipid, since it has roles in malignant transformation,
proliferation, angiogenesis, and resistance to cell death [14].
Inhibition of SK-1 activity was shown to increase cancer cells
sensitivity to anticancer agents [15,16]. Up-regulation of SK-1 and
S1P levels were determined in various types of cancer cells [17,18].
In the current study, we examined the possibility of increasing
sensitivity of prostate cancer cells to docetaxel by increasing
intracellular generation and accumulation of apoptotic ceramides.
We also examined the roles of bioactive sphingolipids in
docetaxel-induced apoptosis.
2. Materials and methods
2.1. Chemicals
Docetaxel was obtained from Sigma (Germany). C8:ceramide, N-
(2-hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl)-decana-
mide, hydrochloride (PDMP), and SK-1 inhibitor were obtained from
Cayman Chemicals (USA), dissolved in DMSO, and stored at 20 8C.
2.2. Cell lines
DU-145 and PC-3 cells were obtained from German Collection
of Microorganisms and Cell Cultures (Germany). They were grown
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fetal bovine serum, and 1% penicillin-streptomycin (Invitrogen,
USA) at 37 8C in 5% CO2. DU-145 cells were established from a 69-
year-old man with prostate carcinoma in 1975 [19] while PC-3
cells were established from a 62-year-old man with fourth grade
prostate cancer [20]. They are both AIPC cells.Fig. 1. Antiproliferative effects of docetaxel (A), C8:ceramide (B), PDMP (C), and SK-
1 Inhibitor (D) on DU-145 and PC-3 cells. The IC50 concentration of docetaxel,
C8:ceramide, IC10 values of PDMP, and SK-1 inhibitor were calculated from cell
proliferation plots. The XTT assays were performed using triplicate samples in at
least two independent experiments. The error bars represent the standard
deviations. Statistical significance was determined using two-way analysis of
variance, and P < 0.05 was considered significant.2.3. Measurement of growth by XTT
IC50 values (drug concentration inhibiting proliferation of 50% of
cell population) of docetaxel and C8:ceramide, and IC10 values of
SK-1 inhibitor, and GCS inhibitor, PDMP, were determined by XTT
assay [21]. In short, 1  104 cells/well were seeded into 96-well
plates containing 100 ml of the growth medium in the absence or
presence of increasing concentrations of agents and then incubated
at 37 8C in 5% CO2. After 72 h, cells were treated with 50 ml XTT for
4 h. Then, the plates were read at 492 nm by Elisa reader (Thermo
Electron Corporation Multiskan Spectrum, Finland). Finally, IC
values were calculated from the cell proliferation plots. In order
to determine possible synergism, docetaxel in combination with
C8:ceramide, PDMP, or SK-1 inhibitor were applied to the cells and
the same XTT procedure was applied.
2.4. Isobologram analysis for median dose effect
The CalcuSyn for Windows1 computer program (CalcuSyn
software, Biosoft, UK) was used to perform isobologram analysis of
combinations [22]. Experimental data points, represented by dots
located below, on, or above the line, indicate synergism, additivity,Fig. 2. Synergistic effects of docetaxel in combination with C8:ceramide, PDMP, and
SK-1 inhibitor on proliferation of DU-145 and PC-3 cells. Antiproliferative effects of
combinations were determined by the XTT cell proliferation test in a 72 h culture.
The XTT assays were performed using triplicate samples in at least two independent
experiments. The error bars represent the standard deviation. Statistical
significance was determined using two-way analysis of variance, and P < 0.05
was considered significant.
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effects of two agents, using a median effect plot analysis. A CI
value < 1 indicates synergistic effect (0.1–0.5 strong synergism;
< 0.1 very strong synergism); CI value of 1 indicates additive
effect; and CI value > 1 indicates antagonistic effect (3.3–10 strong
antagonism, > 10 very strong antagonism).Fig. 3. Isobologram analysis of combination of docetaxel with C8:cera2.5. Measurement of caspase-3 enzyme activity
Changes in caspase-3 activity were determined using the
caspase-3 colorimetric assay (R&D Systems, USA) [17]. The cells
that had been induced to apoptosis were collected by centrifu-
gation at 1000 rpm for 10 min. Then, the collected cells weremide, PDMP and SK-1 inhibitor in DU-145 (A) and PC-3 (B) cells.
Fig. 3. (Continued ).
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incubation of the cells on ice for 10 min, they were centrifuged at
14000 rpm for 1 min. Supernatants were taken to new eppendorf
tubes and the reaction mixture was prepared in 96-well plates
adding 20 ml of assay buffer (5 ), 25 ml of sample, 50 ml of
sterilized water, and 5 ml of caspase-3 colorimetric substrate.
After 2 hours of incubation at 37 8C in CO2 incubator, the plate was
read at 405 nm.
2.6. Detection of the loss of mitochondrial membrane potential (MMP)
APO LOGIX JC-1 Assay Kit (Cell Technology, USA) was used to
measure the MMP in DU-145 and PC-3 cells [17]. At the beginning,
the cells that had been induced to apoptosis were collected by
centrifugation at 1000 rpm for 10 min. Supernatants were
removed and 500 ml of JC-1 dye (1%) was added onto the pellets.
After incubation of cells for 15 min at 37 8C in CO2 incubator, they
were centrifuged at 1000 rpm for 5 min. Then, 2 ml of assay buffer
was added onto the pellets and they were centrifuged for 5 min atFig. 4. Fold changes in cytoplasmic/mitochondrial JC-1 in DU-145 and PC-3 cells expos
results are the means of two independent experiments. The error bars represent the stand
the graphs. P < 0.05 was considered significant.1000 rpm again. All pellets were resuspended with 500 ml assay
buffer and 150 ml from each of them was added into the 96-well
plate in triplicate. The aggregate red form which remains within
the intact mitochondria has absorption/emission maxima of 585/
590 nm and the green monomeric form which is released to the
cytoplasm due to the loss of MMP has absorption/emission
maxima of 510/527 nm.
2.7. Total RNA isolation from cells and Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR)
The cells were incubated in the absence and presence of
increasing concentrations of docetaxel, and total RNAs were isolated
by using RNA Isolation Kit (Macherey-Nagel, USA). mRNAs from the
total RNA population were reverse-transcribed into cDNA by using
reverse transcriptase enzyme (Moroney Murine Leukemia Virus
Reverse Transcriptase, Fermentas, USA). The resulting total cDNA
was used in PCR to measure the mRNA levels of LASS1-6, SK-1, and
GCS. mRNA levels of b actin were used as internal positive control.ed to combinations of docetaxel with C8:ceramide, PDMP, and SK-1 inhibitor. The
ard deviations, and when not seen, they are smaller than the thickness of the lines on
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3.1. Antiproliferative effects of docetaxel, C8:ceramide, PDMP and SK-
1 inhibitor on prostate cancer cells
IC50 values of docetaxel for DU-145 and PC-3 were found to be
30 and 38,4 nM (Fig. 1A), respectively. Dose-dependent decreases
in proliferation of DU-145 and PC-3 cells were detected in response
to C8:ceramide (IC50: 33 and 35 mM, respectively, Fig. 1B), PDMP
(IC10: 100 and 85 mM, respectively, Fig. 1 C) and SK-1 inhibitor
(IC10:32 and 92 mM, respectively, Fig. 1D).
3.2. Increasing intracellular concentrations of ceramides sensitized
prostate cancer cells to docetaxel
Increasing concentrations of docetaxel with the IC50 value of
C8:ceramide or IC10 values of PDMP or SK-1 inhibitor were applied
to DU-145 and PC-3 cells to determine possible synergistic
cytotoxicity. The data revealed that docetaxel in combination
with C8:ceramide (Fig. 2A), PDMP (Fig. 2B) and SK-1 inhibitor
(Fig. 2C) improved growth-inhibitory effects of docetaxel in both
cells significantly. The CI values obtained by Calcusyn Programme
for combination of docetaxel with C8:ceramide, PDMP and SK-1
inhibitor in DU-145 cells were 5.256E-021, 0.14462, and 1.4137E-
033, respectively (Fig. 3A) while the values were 0.00018, 1.3924E-
015, and 5.9743E-023 in PC-3 cells, respectively (Fig. 3B). All CI
values showed very strong synergism for combination of docetaxel
with the chemicals targeting bioactive sphingolipids.Fig. 5. Fold changes in caspase-3 enzyme activity in response to coadministration of doce
independent experiments. The error bars represent the standard deviations, and when n
considered significant.3.3. Apoptotic effects of docetaxel alone or in combination with
ceramide metabolism targeting agents on prostate cancer cells
It has been shown that docetaxel induces apoptosis in a dose-
dependent manner through loss of MMP and increase of capase-3
enzyme activity in both DU-145 and PC-3 cells. While application
of C8:ceramide, PDMP, or SK-1 inhibitors alone induced apoptosis,
docetaxel in combination with C8:ceramide, PDMP or SK-1
inhibitor resulted in apoptosis synergistically. Apoptotic syner-
gism was detected by increases in loss of MMP as compared to any
agent alone or untreated controls in DU-145 (Fig. 4A) and PC-3
(Fig. 4B) cells. In order to confirm MMP and XTT data, we
monitored the changes in caspase-3 enzyme activity in both DU-
145 (Fig. 5A) and PC-3 (Fig. 5B) cells. Changes in caspase-3 enzyme
activity in DU-145 and PC-3 cells confirmed previous data
indicating synergistic apoptotic effects of docetaxel with sphingo-
lipids targeting agents.
3.4. Expression levels of ceramide metabolizing genes in response to
docetaxel
The roles of ceramide metabolising genes in docetaxel-induced
apoptosis were investigated by examining mRNA levels of LASS1-6,
SK-1, and GCS genes in human prostate cancer cells exposed to
increasing concentrations of docetaxel for 72 h. Significant
decreases in expression levels of SK-1 and GCS genes were detected
in both cells in response to docetaxel as compared to untreated
controls and normalized to b actin levels (Fig. 4). There were notaxel with C8:ceramide, PDMP, and SK-1 inhibitor. The results are the means of two
ot seen, they are smaller than the thickness of the lines on the graphs. P < 0.05 was
Fig. 6. mRNA levels of ceramide metabolising genes in response to docetaxel in DU-
145 (A) and PC-3 (B) cells. 0,1-, 1-, and 10 nM docetaxel were applied to DU-145 and
PC-3 cells for 72 h and expression levels of ceramide metabolising genes were
determined by RT-PCR. Expression levels of b actin was detected as an internal
positive control.
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LASS6 in response to docetaxel in DU-145 cells. Increases in
expression levels of LASS2 and LASS6 but not LASS4 and LASS5
were observed in PC-3 cells. The LASS1 gene, responsible for
C18:ceramide generation, was upregulated in both DU-145 and
PC-3 cells (Fig. 6).
4. Discussion and conclusion
In this study, the roles and mechanisms of action of ceramide
metabolism in the regulation of docetaxel-induced cell death were
examined. The data obtained from this study suggest a novel
mechanism of docetaxel-triggered apoptosis in prostate cancer
cells. The results showed using ceramide analogs/mimetics or
inhibition of GCS and SK-1 enzymes resulted in the increasing
intracellular generation and accumulation of ceramides which
decreased proliferation of prostate cancer cells and induced
apoptosis through loss of MMP and increased caspase-3 enzyme
activity. Above all, the results revealed that the addition of short
chain ceramide, C8:ceramide or PDMP, or SK-1 inhibitor to
docetaxel synergistically increases the sensitivity of prostate
cancer cells, as compared to any agent alone. This study
demonstrated that modulation of bioactive sphingolipids can
provide a promising alternative approach for the treatment of
AIPC.Strategies that either mimic/antagonize bioactive sphingolipids
or modulate their levels could provide a new way for treatment of
cancer. Accumulating ceramide levels by molecular and/or
biochemical methods has proved to increase apoptotic effects of
different chemotherapeutic agents in various types of cancers
[17,23]. Combination of short chain ceramide with paclitaxel
increased therapeutic efficiency in both sensitive and multidrug
resistant ovarian cancer cells [9,23]. Application of cell-permeable
exogenous C6-ceramide sensitized different types of cancer cells to
doxorubicin [24]. C(2)-ceramide induced apoptosis in human
colon cancer cells [25] and increased the sensitivity of human
NSCLC H1299 non-small cell lung cancer cells to paclitaxel-
induced apoptosis [26]. A novel ceramide analog AL6 together with
gemcitabine resulted in synergistic cytotoxicity and increased
apoptosis in pancreatic cancer cells [27]. In parallel with these
studies, we have shown that a combination of short chain
C8:ceramide with docetaxel inhibited cell proliferation and
induced apoptosis in prostate cancer cells, synergistically. In
addition, we have shown for the first time that while docetaxel
upregulates expression levels of LASS1 in both PC-3 and DU-145
cells, it up-regulates LASS2 and LASS6 only in PC-3 cells.
An inhibition of GCS and SK-1 provides a novel therapeutic
option for the treatment of various types of cancers. Likewise, it has
been shown that a combination of docetaxel with GCS or SK-1
inhibitors suppressed proliferation of prostate cancer cells and
induced apoptosis synergistically. Dose-dependent decreases in
expression levels of GCS and SK-1 in response to docetaxel in both
cells were also observed. Dijkhuis et al. showed that inhibition of
GCS by PDMP increased sensitivity of neuroblastoma cells to
paclitaxel through inhibition of cell cycle progression [28]. It was
also demonstrated that increasing accumulation of ceramides by
inhibition of GCS increased sensitivity of p53 mutant human
ovarian cancer cells to doxorubicine [29].
In conclusion, these results show that targeting ceramide
metabolism by increasing its generation and/or accumulation
might provide improved strategies for the treatment of prostate
cancer. More importantly, the data presented here also show for
the first time that docetaxel induces apoptosis in prostate cancer
cells through increasing intracellular generation and accumulation
of ceramides.
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